Search Result

Results for "

INa

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Autophagy (2) Calcium Channel (11) Cytochrome P450 (1) Drug-Linker Conjugates for ADC (1) Estrogen Receptor/ERR (1) HSP (1) Indoleamine 2,3-Dioxygenase (IDO) (1) Insulin Receptor (1) Interleukin Related (1) Isotope-Labeled Compounds (2) MyD88 (1) NF-κB (1) Potassium Channel (6) Small Interfering RNA (siRNA) (1) Sodium Channel (18)
By Research Areas:	Cancer (11) Cardiovascular Disease (17) Metabolic Disease (1) Neurological Disease (2)
Oligonucleotides:	Pre-designed siRNA Sets (1) siRNAs (1)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-108767

Insulin aspart B28Asp; B28-Asp-insulin; INa-X 14; Insulin X 14	Insulin Receptor	Metabolic Disease
Insulin aspart (B28Asp) is a fast-acting analog of human insulin. Insulin aspart provides more rapid absorption than regular human insulin after subcutaneous administration. Insulin aspart can be used for researching diabetes .

HY-110195

Smurf1-IN-A01 1 Publications Verification A01	HSP Interleukin Related MyD88 NF-κB Estrogen Receptor/ERR	Others Cancer
Smurf1-IN-A01 is a Smurf1 inhibitor. Smurf1-IN-A01 has anticancer activity and can be used for the research of osteoporosis and age-related macular degeneration .

HY-12593

GS967 Maximum Cited Publications 8 Publications Verification	Sodium Channel	Cardiovascular Disease
GS967 (GS-458967) is a potent, and selective inhibitor of cardiac late sodium current (late *I_Na* ) with IC₅₀ values of 0.13 and 0.21 μM for ventricular myocytes and isolated hearts, respectively.

HY-N6868

Dimethyl lithospermate B dmLSB	Sodium Channel	Cardiovascular Disease
Dimethyl lithospermate B (dmLSB) is a selective Na ⁺ channel agonist. Dimethyl lithospermate B slows inactivation of sodium current (INa), leading to increased inward current during the early phases of the action potential (AP) .

HY-17401

Ranolazine dihydrochloride 4 Publications Verification CVT 303 dihydrochloride; RS 43285	Calcium Channel Sodium Channel Autophagy	Cardiovascular Disease Cancer
Ranolazine dihydrochloride (CVT 303 dihydrochloride) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (I_Na and I_Kr with IC₅₀ values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine dihydrochloride is also a partial fatty acid oxidation inhibitor .

HY-W010950A

Flecainide hydrochloride 1 Publications Verification	Potassium Channel Sodium Channel	Cardiovascular Disease
Flecainide hydrochloride is a potent and orally active antiarrhythmic agent. Flecainide hydrochloride blocks the cardiac fast inward Na ⁺ current (INa) and the rapid component of the delayed rectifier K ⁺ current. Flecainide hydrochloride prolongs the action potential duration (APD) in ventricular and atrial muscle fibres. Flecainide hydrochloride has the potential for the research of fetal tachycardias .

HY-RS06802

INA Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
INA Human Pre-designed siRNA Set A contains three designed siRNAs for INA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

INA Human Pre-designed siRNA Set A INA Human Pre-designed siRNA Set A

HY-163549

APN-PEG5-VC-PAB-MMAE	Drug-Linker Conjugates for ADC	Cancer
APN-PEG5-VC-PAB-MMAE is a drug-linker conjugate part of INA03 (a transferrin-competitive antibody-drug conjugate against CD71) .

HY-156976

Sulcardine	Calcium Channel Sodium Channel	Cardiovascular Disease
Sulcardine is a multi-ion channel blocker that can reduce I_Na and I_Ca with IC₅₀ values of 26.9 µM and 69.2 µM, respectively. Sulcardine is a potent hNav1.5 channel blocker with a mild inhibitory effect on hERG channels. Sulcardine has anti-arrhythmic effects .

HY-156976A

Sulcardine hydrochloride	Calcium Channel Sodium Channel	Cardiovascular Disease
Sulcardine hydrochloride is a multi-ion channel blocker that can reduce I_Na and I_Ca with IC₅₀ values of 26.9 µM and 69.2 µM, respectively. Sulcardine hydrochloride is a potent hNav1.5 channel blocker with a mild inhibitory effect on hERG channels. Sulcardine hydrochloride has anti-arrhythmic effects .

HY-W010950

Flecainide 1 Publications Verification	Potassium Channel Sodium Channel	Cardiovascular Disease
Flecainide is a potent and orally active antiarrhythmic agent. Flecainide blocks the cardiac fast inward Na ⁺ current (INa) and the rapid component of the delayed rectifier K ⁺ current. Flecainide prolongs the action potential duration (APD) in ventricular and atrial muscle fibres. Flecainide has the potential for the research of fetal tachycardias .

HY-B0280

Ranolazine 4 Publications Verification CVT 303; RS 43285-003	Sodium Channel Calcium Channel	Cardiovascular Disease Cancer
Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (I_Na and I_Kr with IC₅₀ values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor . Antianginal agent.

HY-108579

UCL 1684 dibromide	Potassium Channel	Cardiovascular Disease
UCL 1684 (dibromide) is a first nanomolar, non-peptidic small conductance calcium-activated potassium (SK) channel blocker. UCL 1684 (dibromide) is effective in preventing the development of atrial fibrillation due to potent atrial-selective inhibition of I_Na. UCL 1684 (dibromide) causes atrial-selective prolongation of ERP secondary to induction of postrepolarization refractoriness .

HY-17401S

Ranolazine-d8 dihydrochloride CVT 303-dd₈ dihydrochloride; RS 43285-d₈	Calcium Channel Sodium Channel Autophagy	Cardiovascular Disease Cancer
Ranolazine-d₈ (dihydrochloride) is the deuterium labeled Ranolazine dihydrochloride. Ranolazine dihydrochloride (CVT 303 dihydrochloride) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine dihydrochloride is also a partial fatty acid oxidation inhibitor[3].

HY-148792

Relutrigine PRAX-562	Sodium Channel	Neurological Disease
Relutrigine (PRAX-562) is an orally active inhibitor of persistent sodium channel. Relutrigine potently and preferentially inhibits persistent I_Na induced by ATX-II (Nav 1.5 activator) or the SCN8A mutation N1768D with IC₅₀ values of 141 nM and 75 nM, respectively. Relutrigine exhibits potent use-dependent block and reduces neuronal intrinsic excitability. Relutrigine has effective anticonvulsant activity .

HY-W010950R

Flecainide (Standard)	Potassium Channel Sodium Channel	Cardiovascular Disease
Flecainide (Standard) is the analytical standard of Flecainide. This product is intended for research and analytical applications. Flecainide is a potent and orally active antiarrhythmic agent. Flecainide blocks the cardiac fast inward Na ⁺ current (INa) and the rapid component of the delayed rectifier K ⁺ current. Flecainide prolongs the action potential duration (APD) in ventricular and atrial muscle fibres. Flecainide has the potential for the research of fetal tachycardias .

HY-B0280S2

Ranolazine-d3	Sodium Channel Calcium Channel	Cardiovascular Disease Cancer
Ranolazine-d₃ is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor[3]. Antianginal agent.

HY-B0280S1

Ranolazine-d8	Isotope-Labeled Compounds Sodium Channel Calcium Channel	Cardiovascular Disease Cancer
Ranolazine-d₈ is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor[3]. Antianginal agent.

HY-B0280S

Ranolazine-d5 CVT 303-d₅; RS 43285-003-d₅	Isotope-Labeled Compounds Sodium Channel Calcium Channel	Cardiovascular Disease Cancer
Ranolazine-d₅ is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor[3]. Antianginal agent.

HY-126005

VGSC blocker-1	Sodium Channel	Cancer
VGSC blocker-1 is a potent and small molecule blocker of neonatal isoform of the VGSC subtype, Nav1.5 (nNav1.5). VGSC blocker-1 blocks INa peak currents 34.9% at 1 μM and inhibits cell invasion 0.3% at 1 μM in human breast cancer cell line MDA-MB-231, without affecting the cell viability .

HY-B0280R

Ranolazine (Standard)	Sodium Channel Calcium Channel	Cardiovascular Disease Cancer
Ranolazine (Standard) is the analytical standard of Ranolazine. This product is intended for research and analytical applications. Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (I_Na and I_Kr with IC₅₀ values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor . Antianginal agent.

HY-144652

IDO1-IN-19	Indoleamine 2,3-Dioxygenase (IDO) Calcium Channel Sodium Channel Potassium Channel Cytochrome P450	Cardiovascular Disease Cancer
IDO1-IN-19 (Compound 17) is an orally active IDO1 inhibitor with an IC₅₀ of CYP2C9 of 8.64 μM. IDO1-IN-19 also acts funciton on cardiac channels, with IC₅₀s of 12 μM (IKr), 40 μM (INa), 8.3 μM (ICa), respectively. IDO1-IN-19 has the potential to study cancer diseases .

HY-111245

AZD-1305	Potassium Channel Calcium Channel Sodium Channel	Cardiovascular Disease Neurological Disease
AZD-1305 is an antiarrhythmic agent and atrial selective sodium channel/potassium channel blocker, which can significantly prolongs action potential duration and reduces excitability, cause atrial selective ERP prolongation and acute termination of atrial fibrillation. AZD1305 can be used for atrial fibrillation research .

Cat. No.	Product Name	Target	Research Area

HY-108767

Insulin aspart B28Asp; B28-Asp-insulin; INa-X 14; Insulin X 14	Insulin Receptor	Metabolic Disease
Insulin aspart (B28Asp) is a fast-acting analog of human insulin. Insulin aspart provides more rapid absorption than regular human insulin after subcutaneous administration. Insulin aspart can be used for researching diabetes .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N6868

Dimethyl lithospermate B dmLSB	Cardiovascular Disease Classification of Application Fields Labiatae Source classification Samanea saman (Jacq.) Merr. Phenols Polyphenols Plants Disease Research Fields	Sodium Channel
Dimethyl lithospermate B (dmLSB) is a selective Na ⁺ channel agonist. Dimethyl lithospermate B slows inactivation of sodium current (INa), leading to increased inward current during the early phases of the action potential (AP) .

Cat. No.	Product Name	Chemical Structure

HY-17401S

Ranolazine-d8 dihydrochloride
Ranolazine-d₈ (dihydrochloride) is the deuterium labeled Ranolazine dihydrochloride. Ranolazine dihydrochloride (CVT 303 dihydrochloride) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine dihydrochloride is also a partial fatty acid oxidation inhibitor[3].

Ranolazine-d8 dihydrochloride

Ranolazine-d₈ (dihydrochloride) is the deuterium labeled Ranolazine dihydrochloride. Ranolazine dihydrochloride (CVT 303 dihydrochloride) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine dihydrochloride is also a partial fatty acid oxidation inhibitor[3].

HY-B0280S2

Ranolazine-d3
Ranolazine-d₃ is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor[3]. Antianginal agent.

HY-B0280S1

Ranolazine-d8
Ranolazine-d₈ is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor[3]. Antianginal agent.

HY-B0280S

Ranolazine-d5
Ranolazine-d₅ is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor[3]. Antianginal agent.

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P82322

	alpha Internexin Antibody (YA2067) INa; NEF5; Alpha-internexin; Alpha-Inx; 66 kDa neurofilament protein; NF-66; Neurofilament-66; Neurofilament 5	WB	Human, Mouse, Rat
	alpha Internexin Antibody (YA2067) is a biotin-conjugated non-conjugated IgG antibody, targeting alpha Internexin, with a predicted molecular weight of 55 kDa (observed band size: 55 kDa). alpha Internexin Antibody (YA2067) can be used for WB experiment in human, mouse, rat background.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

INA Human Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
INA Human Pre-designed siRNA Set A contains three designed siRNAs for INA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks